Vertex Pharmaceuticals (NASDAQ:VRTX) Sets New 1-Year High – Time to Buy?

Posted by Geri Gentry on Jul 2nd, 2026

Shares of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX – Get Free Report) reached a new 52-week high on Thursday . The stock traded as high as $512.00 and last traded at $513.60, with a volume of 93462 shares changing hands. The stock had previously closed at $498.01.

Analyst Upgrades and Downgrades

VRTX has been the subject of a number of recent research reports. Truist Financial began coverage on Vertex Pharmaceuticals in a report on Wednesday, May 27th. They issued a “buy” rating and a $542.00 target price for the company. Wall Street Zen lowered Vertex Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Sunday. Royal Bank Of Canada upped their price target on Vertex Pharmaceuticals from $541.00 to $543.00 and gave the company an “outperform” rating in a research report on Tuesday, May 5th. Canaccord Genuity Group dropped their price objective on Vertex Pharmaceuticals from $437.00 to $436.00 and set a “hold” rating for the company in a research note on Tuesday, May 5th. Finally, Maxim Group upgraded shares of Vertex Pharmaceuticals from a “hold” rating to a “buy” rating and set a $575.00 target price on the stock in a research note on Wednesday, March 18th. Twenty-one investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $555.91.

View Our Latest Stock Analysis on Vertex Pharmaceuticals

Vertex Pharmaceuticals Trading Up 4.3%

The stock has a market cap of $131.81 billion, a P/E ratio of 30.87, a price-to-earnings-growth ratio of 2.12 and a beta of 0.29. The business’s fifty day simple moving average is $445.74 and its 200 day simple moving average is $455.42.

Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) last announced its earnings results on Monday, May 4th. The pharmaceutical company reported $4.47 earnings per share for the quarter, topping analysts’ consensus estimates of $4.24 by $0.23. Vertex Pharmaceuticals had a net margin of 35.51% and a return on equity of 23.86%. The company had revenue of $2.99 billion during the quarter, compared to the consensus estimate of $2.99 billion. During the same period in the previous year, the firm posted $4.06 earnings per share. The company’s revenue was up 8.3% on a year-over-year basis. On average, analysts predict that Vertex Pharmaceuticals Incorporated will post 17.02 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Vertex Pharmaceuticals news, EVP Joy Liu sold 1,104 shares of the business’s stock in a transaction dated Friday, May 1st. The stock was sold at an average price of $425.02, for a total transaction of $469,222.08. Following the completion of the sale, the executive vice president directly owned 20,729 shares of the company’s stock, valued at approximately $8,810,239.58. The trade was a 5.06% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Sangeeta N. Bhatia sold 318 shares of the firm’s stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $423.73, for a total transaction of $134,746.14. Following the completion of the transaction, the director directly owned 4,924 shares in the company, valued at $2,086,446.52. This trade represents a 6.07% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 15,833 shares of company stock worth $7,120,702 over the last three months. 0.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of hedge funds and other institutional investors have recently bought and sold shares of VRTX. Motiv8 Investments LLC acquired a new position in shares of Vertex Pharmaceuticals in the 4th quarter valued at $26,000. Swiss RE Ltd. acquired a new stake in shares of Vertex Pharmaceuticals during the fourth quarter worth $28,000. Eagle Bay Advisors LLC bought a new stake in Vertex Pharmaceuticals in the fourth quarter valued at about $29,000. IMG Wealth Management Inc. lifted its stake in Vertex Pharmaceuticals by 277.8% in the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after buying an additional 50 shares during the period. Finally, Ares Financial Consulting LLC acquired a new position in Vertex Pharmaceuticals in the fourth quarter valued at about $33,000. 90.96% of the stock is owned by institutional investors.

Vertex Pharmaceuticals Company Profile

(Get Free Report)

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.